Upregulation of p16INK4A in Peripheral White Blood Cells as a Novel Screening Marker for Colorectal Carcinoma

Asian Pac J Cancer Prev. 2022 Nov 1;23(11):3753-3761. doi: 10.31557/APJCP.2022.23.11.3753.

Abstract

Objective: Screening of colorectal cancer (CRC) is important for the early detection. CRC is relating to aging and immuno-senescence. One such senescent marker is p16INK4A expression in immune cells. The objective of the study is to investigate the protein expression of p16INK4A in peripheral white blood cells as a screening marker for colorectal cancer.

Methods: A case-control studies were conducted. Cases were patients with colorectal cancer and controls were matched with cases based on age and sex. Peripheral blood was collected from patients and controls and the protein p16INK4A was measured with immunofluorescent techniques. The p16INK4A levels from cases and controls were evaluated using ROC analysis to be used as a screening marker in CRC patients. Mean fluorescent intensity of p16INK4A of cases and controls were analyzed in CD45+, CD3+ or CD14+ cells. The p16INK4A levels of cases were also correlated with clinical data.

Result: Statistically significant increased expression of p16INK4A levels were found in cases compared to controls. p16INK4A in peripheral immune cells had 78% sensitivity and 71% specificity which can possibly be used as a diagnosis tool for colorectal cancer. P16INK4A-positive cell percentage and mean florescent intensity were significantly higher in CD45+ cells, CD3 positive cells and CD14 positive cells. No significant correlation was observed with the clinical data and p16INK4A level of CRC patients.

Conclusion: The significant increase of p16 INK4A expression level in peripheral immune cells represents potential for use as a CRC screening marker.

Keywords: Colorectal carcinoma; Immunofluorescence; P16ink4a; immune cells.

MeSH terms

  • Biomarkers
  • Blood Cells
  • Colorectal Neoplasms* / diagnosis
  • Cyclin-Dependent Kinase Inhibitor p16
  • Humans
  • Leukocyte Count
  • Leukocytes*
  • Up-Regulation

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • Biomarkers